MX2018000206A - Moleculas de fusion. - Google Patents

Moleculas de fusion.

Info

Publication number
MX2018000206A
MX2018000206A MX2018000206A MX2018000206A MX2018000206A MX 2018000206 A MX2018000206 A MX 2018000206A MX 2018000206 A MX2018000206 A MX 2018000206A MX 2018000206 A MX2018000206 A MX 2018000206A MX 2018000206 A MX2018000206 A MX 2018000206A
Authority
MX
Mexico
Prior art keywords
fusion molecules
present
aeruginosa
well
biofilm infection
Prior art date
Application number
MX2018000206A
Other languages
English (en)
Inventor
Corvey Carsten
Lange Christian
Schaefer Juergen
Focken Ingo
Kruip Jochen
Rey Astrid
Fraisse Laurent
Jensen Kristian
Rothe Christine
Allersdorfer Andrea
Lunde Bradley
Stump Heike
Calandra Bernhard
Mourez Michael
Hülsmeyer Martin
Hinner Marlon
Wiedenmann Alexander
Rat Dorothea
Stuedemann Thomas
Rasser Hans-Falk
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2018000206A publication Critical patent/MX2018000206A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a moléculas de fusión que tienen especificidad de unión para pioverdina tipo I, II y III y pioquelina y se pueden usar en varias aplicaciones, incluyendo aplicaciones de diagnóstico y/o terapéuticas, por ejemplo, para inhibir o reducir el crecimiento de P. aeruginosa y/o para prevenir o tratar una infección por biopelícula de P. aeruginosa así como enfermedades o trastornos asociados con una infección por biopelícula de P. aeruginosa. La presente invención también se refiere a métodos para producir las moléculas de fusión descritas en la presente invención, así como a composiciones y kits que comprenden dichas moléculas de fusión. La presente invención se refiere además a moléculas de ácido nucleico que codifican las moléculas de fusión descritas en la presente invención.
MX2018000206A 2015-07-07 2016-07-06 Moleculas de fusion. MX2018000206A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306106.4A EP3115371A1 (en) 2015-07-07 2015-07-07 Fusion molecules
PCT/EP2016/065899 WO2017005763A1 (en) 2015-07-07 2016-07-06 Fusion molecules

Publications (1)

Publication Number Publication Date
MX2018000206A true MX2018000206A (es) 2018-02-26

Family

ID=53719726

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000206A MX2018000206A (es) 2015-07-07 2016-07-06 Moleculas de fusion.

Country Status (26)

Country Link
US (2) US10316071B2 (es)
EP (2) EP3115371A1 (es)
JP (1) JP2018524003A (es)
KR (1) KR20180026755A (es)
CN (1) CN107849106A (es)
AR (1) AR105257A1 (es)
AU (1) AU2016289839A1 (es)
BR (1) BR112018000155A2 (es)
CA (1) CA2991298A1 (es)
CL (1) CL2018000015A1 (es)
CO (1) CO2018001188A2 (es)
CR (1) CR20180079A (es)
DO (1) DOP2018000001A (es)
EA (1) EA201890234A1 (es)
EC (1) ECSP18008488A (es)
HK (1) HK1249110A1 (es)
IL (1) IL256694A (es)
MA (1) MA42006A1 (es)
MX (1) MX2018000206A (es)
PE (1) PE20180490A1 (es)
PH (1) PH12018500058A1 (es)
TN (1) TN2017000547A1 (es)
TW (1) TW201716435A (es)
UY (1) UY36772A (es)
WO (1) WO2017005763A1 (es)
ZA (1) ZA201708754B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035824B1 (ru) 2015-02-18 2020-08-17 Пайерис Фармасьютикалс Гмбх Новые белки, специфичные к пиовердину и пиохелину
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
AU2020253034A1 (en) * 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
CN111848734B (zh) * 2020-06-17 2022-04-05 自然资源部第三海洋研究所 一种具有荧光特性的铁载体pvd、制备方法及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
PL192364B1 (pl) 1998-06-08 2006-10-31 Hoffmann La Roche Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP4469456B2 (ja) 2000-04-19 2010-05-26 第一三共株式会社 緑膿菌鉄獲得系阻害物質のスクリーニング法
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7056702B2 (en) 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
EP1814988A2 (en) 2004-11-26 2007-08-08 Pieris AG Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
EP2313430B1 (en) * 2008-06-24 2018-05-02 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
DK2510357T3 (en) 2009-12-07 2016-07-18 Pieris Ag MUTEINS OF HUMAN LIPOCALIN 2 (LCN2, HNGAL) WITH AFFINITY FOR A SPECIFIC TARGET
WO2011149962A1 (en) * 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
WO2014076321A1 (en) * 2012-11-19 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
CN103074303A (zh) * 2012-12-27 2013-05-01 中国人民解放军第三军医大学 产生抗人ngal特异性单克隆抗体的杂交瘤细胞株及其产生的单克隆抗体与应用
EA035824B1 (ru) 2015-02-18 2020-08-17 Пайерис Фармасьютикалс Гмбх Новые белки, специфичные к пиовердину и пиохелину
CA2982034A1 (en) 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules

Also Published As

Publication number Publication date
EP3319986A1 (en) 2018-05-16
DOP2018000001A (es) 2018-05-15
US20170029477A1 (en) 2017-02-02
JP2018524003A (ja) 2018-08-30
TW201716435A (zh) 2017-05-16
HK1249110A1 (zh) 2018-10-26
PE20180490A1 (es) 2018-03-07
CL2018000015A1 (es) 2018-07-13
AR105257A1 (es) 2017-09-20
AU2016289839A1 (en) 2018-03-01
MA42006A1 (fr) 2018-09-28
WO2017005763A1 (en) 2017-01-12
TN2017000547A1 (en) 2019-04-12
CO2018001188A2 (es) 2018-05-10
CR20180079A (es) 2018-04-24
CN107849106A (zh) 2018-03-27
EP3115371A1 (en) 2017-01-11
BR112018000155A2 (pt) 2018-09-11
ECSP18008488A (es) 2018-04-30
US10947284B2 (en) 2021-03-16
EA201890234A1 (ru) 2018-06-29
UY36772A (es) 2017-01-31
KR20180026755A (ko) 2018-03-13
PH12018500058A1 (en) 2018-07-09
US20190382455A1 (en) 2019-12-19
ZA201708754B (en) 2018-11-28
IL256694A (en) 2018-03-29
US10316071B2 (en) 2019-06-11
CA2991298A1 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
PH12017501473A1 (en) Novel proteins specific for pyoverdine and pyochelin
PH12017501921A1 (en) Novel compounds
WO2017191274A3 (en) Rna encoding a therapeutic protein
MX2018012880A (es) Metodos para proporcionar arn de hebra sencilla.
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
MX2017013321A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
PH12018500058A1 (en) Fusion molecules
EA201790273A1 (ru) Флагеллиновые композиции и их применение
BR112017019412A2 (pt) proteínas ligadoras de tslp
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
BR112018014288A2 (pt) métodos e composições para o tratamento de doença neurológica
MX2015005874A (es) Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
EP3598980A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
MX2022006573A (es) Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias.
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
PH12020550023A1 (en) Compositions for treating stress-related disorders
EA201791363A1 (ru) Пиразолопиридинамины в качестве ингибиторов mknk1 и mknk2
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
MX366046B (es) Moléculas de unión que se adhieren al factor de complemento c2 humano y usos de los mismos.
EA201590884A1 (ru) Способы лечения заболеваний печени
MX2011008456A (es) Anticuerpos anti-mst1r y usos de los mismos.
MX2021007271A (es) Nuevas moleculas de acido nucleico conjugado y sus usos.
SE1750774A1 (en) Novel nucleic acid molecules and their use in therapy